UBS Group
ALZN icon

UBS Group’s Alzamend Neuro ALZN Stock Holding History

UBS Group’s Portfolio ALZN Stock Details ALZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.77K Sell
4,504
-20,063
-82% -$40.1K ﹤0.01% 8886
2025
Q4 		$44.7K Buy
24,567
+22,492
+1,084% +$51K ﹤0.01% 7288
2025
Q3 		$4.94K Buy
2,075
+1,173
+130% +$3.05K ﹤0.01% 8912
2025
Q2 		$2.63K Buy
+902
New +$4.47K ﹤0.01% 9436
2025
Q1 		– Sell
-91
Closed -$951 – 10186
2024
Q4 		$951 Buy
+91
New +$1.17K ﹤0.01% 9343
2024
Q3 		– Sell
-57
Closed -$2.02K – 9463
2024
Q2 		$2.02K Buy
+57
New +$3.26K ﹤0.01% 8439
2024
Q1 		– Sell
-21
Closed -$1.7K – 9248
2023
Q4 		$1.7K Buy
21
+15
+250% +$2.46K ﹤0.01% 8241
2023
Q3 		$1.88K Buy
+6
New +$2.87K ﹤0.01% 7809
2023
Q2 		– Sell
-2
Closed -$1.57K – 8462
2023
Q1 		$1.26K Sell
2
-5
-71% -$3.76K ﹤0.01% 8773
2022
Q4 		$5.22K Sell
7
-7
-50% -$10.1K ﹤0.01% 9205
2022
Q3 		$22K Sell
14
-1
-7% -$1.37K ﹤0.01% 7237
2022
Q2 		$18K Buy
15
+3
+25% +$3.89K ﹤0.01% 6986
2022
Q1 		$20K Buy
12
+10
+500% +$18.8K ﹤0.01% 7436
2021
Q4 		$5K Hold
2
– – ﹤0.01% 9369
2021
Q3 		$8K Hold
2
– – ﹤0.01% 8185
2021
Q2 		$24K Buy
+2
New +$25.8K ﹤0.01% 7131

Other funds holding ALZN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

UBS Group's ALZN Position: Q1 2026 in Review

UBS Group reduced its Alzamend Neuro (ALZN) stake by 82% in Q1 2026, selling an estimated $40.1K and leaving 4,504 shares worth $4.77K. The position accounts for ﹤0.01% of the portfolio, ranked #8886.

UBS Group first reported a position in ALZN in Q2 2021 and has held it in 16 quarters since. The position peaked at $44.7K in Q4 2025. 12 funds tracked by Wall St. Rank hold ALZN as of Q1 2026.

  • UBS Group held 4,504 shares of Alzamend Neuro worth $4.77K as of Q1 2026.
  • UBS Group sold 20,063 Alzamend Neuro shares in Q1 2026, an estimated $40.1K.
  • Alzamend Neuro made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #8886 holding.
  • UBS Group first reported a position in Alzamend Neuro in Q2 2021 and has held it in 16 quarters since.
  • UBS Group's Alzamend Neuro position peaked at $44.7K in Q4 2025.
  • 12 funds tracked by Wall St. Rank held Alzamend Neuro as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.